Recombinant human prourokinase for 41 cases of acute myocardial infarction with elevated STª²segment

    GUO Xuan1,LI Chengª²Xiang1,JIA Guoª²Liang1,WANG Haiª²Chang1,JIANG Yan2,FENG Xuª²Yang1,CAO Feng1,GUO Wenª²Yi1,WANG Xiaoª²Yan1,LI Wei1,DANG Miª²Chan1

    1Department of Cardiovasology,Xijing Hospital,Fourth Military Medical University,Xi¡¯an 710033,China,2Shanghai Tasly Biopharmaceutical Co.Ltd,Shanghai 201203,China

    ¡¾Abstract¡¿ AIM: To observe the clinical efficacy and safety of intravenous thrombolytic therapy using recombinant human prourokinase (rhProª²uk) in acute myocardial infarction (AMI).METHODS: Fortyª²one patients with AMI were randomized into Proª²uk group (n=28) and urokinase (UK) group (n=13).The patency of infarctª²related coronary artery at 90 min after administration was assessed by coronary angiography and adverse reaction was also observed.RESULTS: The TIMI 3 grade patency in rhProª²uk group was significantly higher than that in UK group(57% vs 23%,P<0ª±05).The rate of STª²segment depression >50% in rhProª²uk group was significantly higher than that in UK group(75% vs 39%,P<0ª±05).The rate of bleeding was not statistically different between two groups (22% vs 23%,P>0ª±05).No intracranial hemorrhage or major bleeding needing transfusion was observed.CONCLUSION: rhProª²uk is an effective,reliable and safe thrombolytic agent. ......